 |
市場調查報告書
商品編碼
1914086
固體癌治療市場規模、佔有率和成長分析（按治療方法、癌症適應症、最終用戶和地區分類）—2026年至2033年產業預測Solid Tumor Therapeutics Market Size, Share, and Growth Analysis, By Therapy Type (Chemotherapy, Targeted Therapy), By Cancer Indication (Breast Cancer, Lung Cancer), By End User, By Region -Industry Forecast 2026-2033. |
||||||
預計到 2024 年，全球固體癌治療市場規模將達到 1,915.8 億美元，到 2025 年將達到 2,072.9 億美元，到 2033 年將達到 3,894 億美元，預測期（2026-2033 年）的複合年成長率為 8.2%。
由於人口老化和生活方式改變導致風險因素增加，包括乳癌、肺癌、大腸癌和攝護腺癌在內的多種癌症發生率不斷上升，全球固體癌治療市場正經歷強勁成長。對有效治療方案日益成長的需求促使人們採用標靶治療和免疫療法等先進治療方法，這些療法與傳統化療相比，已顯示出更佳的患者療效。新型治療方法的監管核准數量激增以及強大的抗癌藥物研發管線進一步推動了這一成長。此外，製藥公司對基於生物標記和基因組分析的個人化醫療研發投入、醫療費用支出不斷成長以及有利的醫保報銷政策也是推動市場擴張的主要因素。
全球固體癌治療市場按治療方法類型、癌症適應症、最終用戶和地區進行細分。依治療方法類型分類，可分為化療、標靶治療、免疫療法、荷爾蒙療法和其他療法。依癌症適應症分類，可分為乳癌、肺癌、大腸癌、攝護腺癌、肝癌和其他癌症。依最終用戶分類，可分為醫院、癌症研究中心和專科診所。依地區分類，可分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。
推動全球固體癌藥物市場發展的因素
網路攻擊（包括勒索軟體、網路釣魚和資料外洩）的發生率和複雜性不斷增加，加劇了企業面臨的安全漏洞。這種不斷擴大的威脅環境迫使企業加大對防護措施的投入，從而推動了全球固體癌治療市場的成長。各行各業的公司都在積極尋求有效的解決方案來降低風險並確保業務順利運營，這刺激了對創新治療方法的需求。隨著企業將防禦這些威脅列為優先事項，固體癌治療市場展現出強勁的成長勢頭，反映出在應對不斷變化的挑戰時，人們對健康和安全的重視程度日益提高。
限制全球固態腫瘤藥物市場的因素
全球固態腫瘤治療市場面臨許多挑戰，其中，先進療法（尤其是生物製藥和免疫療法）的高昂費用限制了中低收入地區患者的治療機會。有限的保險覆蓋範圍和高額的自付費用進一步阻礙了這些治療方法的應用，尤其是在資源匱乏的地區。這些經濟障礙造成了治療機會的不平等，阻礙了創新治療方法的公平獲取，並最終限制了全球固體癌治療市場的整體成長和滲透。消除這些障礙對於提高全球癌症治療的可近性和公平性至關重要。
全球固體癌抗癌藥物市場趨勢
全球固體癌治療市場正呈現出人工智慧與數位病理學融合的顯著趨勢，這大大促進了治療的個人化。這些先進技術簡化了腫瘤特徵分析，使腫瘤科醫師能夠制定個人化的治療策略，進而改善患者的治療效果。借助人工智慧的分析能力，醫療機構可以提高治療反應預測的準確性，同時加速精準醫療在各種癌症類型中的應用。這種轉變不僅最佳化了個別患者照護，也推動了治療領域的創新，為投資這些前沿解決方案的相關人員帶來了競爭優勢。
目錄
介紹
- 調查目標
- 調查範圍
- 定義
調查方法
- 資訊收集
- 二手資料和一手資料方法
- 市場規模預測
- 市場假設與限制
執行摘要
- 全球市場展望
- 供需趨勢分析
- 細分市場機會分析
市場動態與展望
- 市場規模
- 市場動態
- 促進因素和機遇
- 限制與挑戰
- 波特分析
關鍵市場考察
- 關鍵成功因素
- 競爭程度
- 關鍵投資機會
- 市場生態系統
- 市場吸引力指數（2025）
- PESTEL 分析
- 總體經濟指標
- 價值鏈分析
- 定價分析
- 案例研究
- 顧客購買行為分析
全球固體癌治療藥物市場規模（依治療方法分類）及複合年成長率（2026-2033 年）
- 化療
- 標靶治療
- 免疫療法
- 荷爾蒙療法
- 其他
全球固體癌藥物市場規模（按癌症適應症和複合年成長率分類）（2026-2033 年）
- 乳癌
- 肺癌
- 大腸直腸癌
- 攝護腺癌
- 肝癌
- 其他
全球固體癌治療藥物市場規模（依最終用戶分類）及複合年成長率（2026-2033 年）
- 醫院
- 癌症研究中心
- 專科診所
全球固體癌治療市場規模及複合年成長率（2026-2033）
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
- 亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
- 拉丁美洲
- 巴西
- 其他拉丁美洲地區
- 中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區
競爭資訊
- 前五大公司對比
- 主要企業的市場定位（2025 年）
- 主要市場參與者所採取的策略
- 近期市場趨勢
- 公司市佔率分析（2025 年）
- 主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較
主要企業簡介
- Roche Holding AG（Switzerland）
- Novartis AG（Switzerland）
- AstraZeneca plc（United Kingdom）
- Bristol Myers Squibb Company（USA）
- Merck & Co., Inc.（USA）
- Pfizer Inc.（USA）
- Amgen Inc.（USA）
- Eli Lilly and Company（USA）
- Johnson & Johnson（USA）
- AbbVie Inc.（USA）
- Sanofi SA（France）
- Bayer AG（Germany）
- Takeda Pharmaceutical Company Limited（Japan）
- Gritstone Bio, Inc.（USA）
- Black Diamond Therapeutics, Inc.（USA）
結論與建議
Global Solid Tumor Therapeutics Market size was valued at USD 191.58 Billion in 2024 and is poised to grow from USD 207.29 Billion in 2025 to USD 389.4 Billion by 2033, growing at a CAGR of 8.2% in the forecast period (2026-2033).
The global solid tumor therapeutics market is experiencing robust growth due to rising incidences of various cancers, such as breast, lung, colorectal, and prostate cancers, fueled by an aging population and lifestyle changes that elevate risk factors. The demand for effective therapeutic solutions is increasing, leading to the adoption of advanced treatments like targeted therapies and immunotherapies, which are demonstrating improved patient outcomes compared to traditional chemotherapy. This growth is further supported by a surge in regulatory approvals for novel treatments and a strong pipeline of oncology drugs. Pharmaceutical investments in research and development for personalized medicine, enhanced by biomarkers and genomic profiling, alongside higher healthcare expenditures and favorable reimbursement rates, are key factors boosting market expansion.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Solid Tumor Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Solid Tumor Therapeutics Market Segments Analysis
The global solid tumour therapeutics market is segmented based on therapy type, cancer indication, end user, and region. In terms of therapy type, the market is divided into chemotherapy, targeted therapy, immunotherapy, hormone therapy, and others. Based on cancer indication, the market is categorized into breast cancer, lung cancer, colorectal cancer, prostate cancer, liver cancer, and others. Based on end user, the market is segmented into hospitals, cancer research centers, and specialty clinics. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
Driver of the Global Solid Tumor Therapeutics Market
The rising incidence and complexity of cyberattacks, such as ransomware, phishing, and data breaches, have heightened the vulnerabilities faced by organizations. This growing threat environment prompts businesses to expand their investments in protective measures, thereby driving the growth of the global solid tumor therapeutics market. Companies across various sectors are increasingly seeking effective solutions to mitigate risks and ensure seamless operations, fueling demand for innovative therapies. As organizations prioritize safeguarding against these threats, the market for solid tumor therapeutics is witnessing significant momentum, reflecting a broader commitment to health and security in the face of evolving challenges.
Restraints in the Global Solid Tumor Therapeutics Market
The Global Solid Tumor Therapeutics market faces significant challenges due to the high costs associated with advanced treatments, particularly biologics and immunotherapies, which restrict access for patients in lower- and middle-income areas. Limited insurance coverage and substantial out-of-pocket expenses further hinder the adoption of these therapies, especially in resource-constrained environments. These financial obstacles create disparities in treatment availability, preventing a fair distribution of innovative therapies and ultimately limiting the overall growth and penetration of the global solid tumor therapeutics market. Addressing these barriers is crucial for enhancing accessibility and equality in cancer treatment worldwide.
Market Trends of the Global Solid Tumor Therapeutics Market
The Global Solid Tumor Therapeutics market is witnessing a notable trend towards the integration of AI and digital pathology, significantly enhancing treatment personalization. These advanced technologies streamline tumor characterization, enabling oncologists to develop tailored therapeutic strategies that improve patient outcomes. By leveraging AI's analytical capabilities, healthcare providers can enhance the predictability of treatment responses while expediting the adoption of precision medicine across various cancer types. This shift not only optimizes individual patient care but also drives innovation within the therapeutic landscape, establishing a competitive edge for stakeholders who invest in these cutting-edge solutions.
Table of Contents
Introduction
- Objectives of the Study
- Scope of the Report
- Definitions
Research Methodology
- Information Procurement
- Secondary & Primary Data Methods
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Global Market Outlook
- Supply & Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Overview
- Market Size
- Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
- Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers
Key Market Insights
- Key Success Factors
- Degree of Competition
- Top Investment Pockets
- Market Ecosystem
- Market Attractiveness Index, 2025
- PESTEL Analysis
- Macro-Economic Indicators
- Value Chain Analysis
- Pricing Analysis
- Case Studies
- Customer Buying Behavior Analysis
Global Solid Tumor Therapeutics Market Size by Therapy Types & CAGR (2026-2033)
- Market Overview
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Hormone Therapy
- Others
Global Solid Tumor Therapeutics Market Size by Cancer Indication & CAGR (2026-2033)
- Market Overview
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Liver Cancer
- Others
Global Solid Tumor Therapeutics Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Cancer Research Centers
- Specialty Clinics
Global Solid Tumor Therapeutics Market Size & CAGR (2026-2033)
- North America (Therapy Types, Cancer Indication, End User)
- US
- Canada
- Europe (Therapy Types, Cancer Indication, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Therapy Types, Cancer Indication, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Therapy Types, Cancer Indication, End User)
- Brazil
- Rest of Latin America
- Middle East & Africa (Therapy Types, Cancer Indication, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gritstone Bio, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Black Diamond Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations
